Burning Fat, Not Just Eating Less: A Chattanooga Physician on GLP-1/Glucagon Drugs

Updated July 2026
Frontier Science · Summit Metabolic Health

Burning Fat, Not Just Eating Less: A Chattanooga Physician on GLP-1/Glucagon Drugs

Today’s weight-loss medications mostly work by turning down your appetite. The next frontier does something different — it also turns up the rate at which your body burns fat. The leading example is an investigational GLP-1/glucagon drug called pemvidutide, and its most interesting claim is about the quality of the weight you lose, not just the amount. I’m a Chattanooga physician, and I want to explain the science and, more importantly, what you can do about it in Tennessee today.

I am Dr. Paul Miranda, a board-certified physician at Summit Metabolic Health. I read every patient chart myself. When patients hear about a drug that “burns fat instead of muscle,” they get excited — and they should understand it clearly, because the principle behind it is something I already build into every plan I write.

Adding Glucagon: The GLP-1/Glucagon Fat-Burning Idea

A GLP-1 medication works mainly on appetite — it makes you feel full sooner and less preoccupied with food. Pemvidutide adds a second hormone to that signal: glucagon. In this balanced GLP-1/glucagon design, the GLP-1 side still curbs appetite, while the glucagon side raises energy expenditure and pushes the body to oxidize — to burn — stored fat, particularly in the liver (Altimmune MOMENTUM Phase 2 program; pemvidutide clinical development, PMID 39002641). In plain terms: one lever eats less, the other lever spends more.

That combination matters for a problem every honest weight-loss doctor worries about. When you lose weight quickly, some of what you lose is muscle, not just fat. The hope with a glucagon-driven drug is that it preferentially mobilizes fat — protecting more of your lean muscle along the way.

What the Early Data Actually Show

In its Phase 2 obesity trial (MOMENTUM), the highest dose of pemvidutide was associated with about 15.6 percent average weight loss at 48 weeks, versus about 2.2 percent on placebo — and the weight curve had not flattened out at the end of the study. The headline that got researchers’ attention was the body-composition breakdown: roughly 78 percent of the weight lost came from fat and about 22 percent from lean mass, which the manufacturer describes as favorable muscle preservation. In a separate Phase 2b study in metabolic liver disease, pemvidutide resolved the liver condition in about 52 to 58 percent of patients versus 20 percent on placebo (IMPACT trial, Lancet 2025, PMID 41237796). Trial averages, not guarantees — individual results vary.

~78%
Share of weight lost that came from fat (versus ~22% lean mass) in the Phase 2 body-composition analysis of investigational pemvidutide — the muscle-preservation signal driving interest in GLP-1/glucagon drugs. Sponsor analysis, not a head-to-head trial; individual results vary; drug not FDA-approved.

Keep this in perspective: pemvidutide is investigational — not FDA-approved and not prescribable as of July 2026, with large Phase 3 obesity trials still ahead. The lean-mass claim is promising but comes from the company’s own analysis, not a head-to-head comparison, so treat it as an encouraging early signal rather than settled fact. And it is not side-effect-free: at the higher obesity dose, gastrointestinal effects led roughly one in five trial participants to stop the drug. A stronger mechanism always demands more careful management, not less.

The Real Lesson: The Quality of Your Weight Loss Matters

Whether or not pemvidutide ever reaches a pharmacy, it has already made a point I make to patients every week in Chattanooga: how much you weigh is only half the story. What that weight is made of — fat versus muscle — is the other half. Muscle is your metabolic engine. Lose too much of it, and you become someone who is lighter but weaker, with a slower metabolism that makes regaining weight easier. That is not a win.

Here is the part the drug companies cannot patent: you do not need an experimental glucagon drug to protect your muscle while you lose fat. We already know how to do it. It just requires a physician who is paying attention to more than the scale.


What I Do for Patients at Summit Today

At Summit Metabolic Health, “muscle-sparing fat loss” is not a future promise — it is how I run every plan. I use the proven, FDA-approved medications available now, and I surround them with the things that protect your lean mass while the fat comes off.

The Summit Muscle-Protective Protocol
Available now · Physician-managed · TN · FL · GA · OH · WA

In Practice

Protein
Set high to protect muscle
Training
Resistance work, not just cardio
Pace
Deliberate dosing, no crash
Tracking
Body composition, not just lbs

A drug that spares muscle is still years away. A doctor who protects your muscle is available to you in Tennessee right now.

This is exactly where a physician-led program and a telehealth refill mill part ways. A questionnaire scored by software hands out a dose and never asks what your weight is made of. It does not set your protein target, program resistance training, or slow your titration so the loss stays fat and not muscle. That attention is the whole point — and it is why I read every chart at Summit myself before anyone gets a plan.

The frontier drugs are chasing “muscle-sparing fat loss.” I don’t need to chase it — protein, resistance training, and a careful pace deliver it today.Paul Miranda, MD — Summit Metabolic Health

And because Summit builds an exit strategy into every plan — reach your goal weight, then taper the medication in a controlled way — the muscle you protected and the fat you lost are meant to last. It is also the program designed to get cheaper as you get healthier.

The Bottom Line for Chattanooga

GLP-1/glucagon drugs like pemvidutide point to an important truth: the goal was never just a smaller number, it was losing fat while keeping the muscle that keeps you strong and your metabolism healthy. That is genuinely exciting science — but it is investigational and years away. The good news is that the strategy behind it is available in Tennessee today, with a physician who tracks what your weight is actually made of.

Want to lose fat without losing your strength? Book a free 20-minute consultation with Dr. Miranda.

Request Your Free Consultation

You can apply in about five minutes at summitmetabolichealth.com/apply. I personally review every application and reach out — no algorithms, no sales calls.

This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Pemvidutide is an investigational drug that is not FDA-approved and cannot be prescribed as of July 2026; efficacy and body-composition figures are from Phase 2 studies, are group averages, and individual results vary and are not guaranteed. The lean-mass figure reflects a sponsor analysis, not a head-to-head comparison. Semaglutide and tirzepatide are prescription medications with risks and contraindications that require physician evaluation. Summit Metabolic Health serves patients in Tennessee, Florida, Georgia, Ohio, and Washington.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *